09.12.13
Delphinus Medical Inc., a small company that has developed a whole breast tomography system, has been granted a $6 million dollar land from GE’s Healthcare Financial Services division. The multi-draw loan will be used, according to Delphinus officials, for clinical and early commercialization efforts.
“GE delivered extremely competitive financing that met our needs directly,” said William Greenway, CEO of Delphinus Medical Technologies. “They also impressed us with their ability to move quickly through the process and close a complex transaction in a short timeframe.”
“Utilizing our industry and finance expertise, we customized financing that aligned with Delphinus’ short and long-term capital needs,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. “We will continue to work closely with Delphinus as they move down the path of developing and commercializing their innovative technology.”
Plymouth, Mich.-based Delphinus Medical Technologies’ flagship product is the breast tomography system SoftVue. The patented technology is designed to operate without radiation or compression and is reportedly not dependent on operator skills. Delphinus has filed with the U.S. Food and Drug Administration for clearance to commercialize the technology.
“GE delivered extremely competitive financing that met our needs directly,” said William Greenway, CEO of Delphinus Medical Technologies. “They also impressed us with their ability to move quickly through the process and close a complex transaction in a short timeframe.”
“Utilizing our industry and finance expertise, we customized financing that aligned with Delphinus’ short and long-term capital needs,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. “We will continue to work closely with Delphinus as they move down the path of developing and commercializing their innovative technology.”
Plymouth, Mich.-based Delphinus Medical Technologies’ flagship product is the breast tomography system SoftVue. The patented technology is designed to operate without radiation or compression and is reportedly not dependent on operator skills. Delphinus has filed with the U.S. Food and Drug Administration for clearance to commercialize the technology.